REGENXBIO (RGNX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on REGENXBIO (RGNX) is Neutral.

The composite score behind that read is -0.03, weighing +0.14 of bullish evidence against -0.28 bearish.

REGENXBIO last closed at $8.07, -0.25% on the session.

Against the IVW growth benchmark the position is -1.05% over the forecast window.

The read is built from 15 underlying insights — 6 bullish and 9 bearish.

Agreement across those insights is 60%.

10 graded predictions for RGNX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks REGENXBIO in the 5th percentile on return on equity, where 100 is best.

REGENXBIO is classified under Health Care / Biotechnology, with a market capitalisation of $534.05M.

StockMap tracks REGENXBIO as the 173rd largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite REGENXBIO ranks 138th of 381 in the group, against a group median of -0.08.